Depressive Burden and Interoceptive Disturbance Improve after Bromocriptine Treatment in Women With Microprolactinomas
Authors' conclusion
Women with microprolactinomas showed improvements in both emotional symptoms and interoceptive awareness following bromocriptine treatment. Emotional disturbances in these patients may be more closely associated with altered interoceptive processing than with prolactin levels themselves.
Study context
- Population
- Women with microprolactinoma and female healthy controls20 completed post-treatment
- Participants
- 52 vs 39
- Exposure
- Women with microprolactinoma vs female healthy controls; before vs after 6 months of bromocriptine
- Patientsn = 52
- Controlsn = 39reference
- Outcome
- Depressive symptoms (BDI) and interoceptive awareness (BPQ)
- Follow-up
- After 6 months of bromocriptine therapy
Methodological detailshealthy-control comparison, longitudinal
- Healthy-control comparison
- Longitudinal
Main finding
As reported in the abstract
6 months
- Post-treatment vs Baseline: P < 0.001
- Post-treatment vs Baseline: P = 0.026
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Baseline BDI and BPQ scoresPatients vs Controls · significantly higher in patients | P = 0.011 |
| Baseline BDI and BPQ scoresPatients vs Controls · significantly higher in patients | P = 0.049 |
Association of prolactin with Body Perception Questionnaire (BPQ) and Beck Depression Inventory (BDI)
- Prolactin associated with BPQ
- P = 0.001
- Prolactin not associated with BDI
- P = 0.259
BPQ added to BDI model
- BPQ remained a significant predictor of depressive symptoms
- P < 0.001
- Effects of time and prolactin no longer significant
Original publication
Depressive Burden and Interoceptive Disturbance Improve after Bromocriptine Treatment in Women With Microprolactinomas. Endocr Pract. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →